Personalized risk assessment for endometrial cancer
Part of Cancer, Women’s health & pregnancy clinical trials.
This trial uses a prediction model to better estimate the risk of endometrial cancer coming back. It aims to help doctors and patients make more personalized treatment decisions after surgery.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have early stage (FIGO stage I or II) endometrial cancer
- Any grade of your cancer is allowed
- You are able to have surgery as your main treatment (chemotherapy or hormone therapy before surgery is okay)
- You are not a native speaker of Dutch or English but can understand one of these languages
- You do not have a rare type of endometrial cancer like endometrial stromal sarcoma
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study uses a tumor “biomarker” test to guide treatment in people with endometrial cancer (and sometimes epithelial ovarian cancer). It tests whether tailoring weekly chemotherapy (paclitaxel) based on biomarker levels can help patients, especially when the cancer has come back or is advanced.
This study looks at combining genetic testing with surgical exams to better understand endometrial cancer. It may help doctors see which treatments could work best for you.
This trial looks at better ways to predict how aggressive your endometrial cancer is before surgery, so doctors can decide if they need to check your lymph nodes. It may help tailor your treatment to avoid unnecessary procedures.
This trial tests whether using tumor “molecular” results plus standard risk factors can guide the best type and timing of radiation after surgery for early-stage endometrial cancer. It may help you avoid under- or overtreatment by matching radiotherapy to your specific risk.
This trial tests whether removing only the first lymph node to detect cancer spread (sentinel node mapping) is as effective as removing all lymph nodes in the pelvic area (comprehensive lymphadenectomy) for a specific type of endometrial cancer with a p53 mutation, stages I–II. The goal is to see if the less extensive surgery can result in similar outcomes while possibly reducing side effects.
This study uses a risk model to detect endometrial cancer in people with unexplained abnormal uterine bleeding. It aims to find better ways to identify cancer early without relying only on invasive biopsies.
Hear when a new Endometrial Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.